Appili Therapeutics, a biopharmaceutical company specializing in infectious disease treatments and vaccines, has secured CAD $100 million in funding for its research and development. The company is pioneering new therapies for global infectious disease and biodefense markets.
Appili’s portfolio of drugs and vaccines addresses pressing medical needs. LIKMEZ, an FDA-approved antibiotic suspension, provides a convenient and safe administration option for patients with swallowing difficulties. Its unique formulation minimizes the risk of infection complications.
Furthermore, Appili’s ATI-1701 vaccine targets tularemia, a highly contagious bacterial infection classified as a Category A pathogen. This vaccine holds promise for improving public health and national security by mitigating the threat posed by tularemia.
Appili plans to acquire all outstanding Class A common shares of Aditxt through a court-approved plan of arrangement. This transaction, subject to certain conditions and regulatory approvals, is anticipated to close by September 30, 2024. The merged entity will combine Appili’s expertise in infectious disease therapeutics with Aditxt’s innovation capabilities, enhancing its pipeline and addressing unmet medical needs.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
